Steven N. Kalkanis, MD
Following a national search, Henry Ford Health System has selected its own Steven N. Kalkanis, MD, as Chief Executive Officer of the Henry Ford Medical Group. He succeeds William A. Conway, MD, who is stepping down after more than 4 decades with the health system.
Dr. Kalkanis will provide strategic leadership and direction to the 1,900-member group of physicians and researchers and will be responsible for all aspects of clinical performance across 40 specialties. Additionally, Dr. Kalkanis will also serve as Henry Ford’s Senior Vice President and Chief Academic Officer, working to advance the health system’s academic mission, including the development and advancement of all research and medical education programs.
In addition, Dr. Kalkanis will also work collaboratively with health system clinical and operational leaders, as well as national and community partners, to provide patient care and advance the system’s population health and accountable care strategies.
Experience and Education
Dr. Kalkanis joined Henry Ford in 2004 and is currently Chair of the health system’s Department of Neurosurgery. He is also Medical Director of the Henry Ford Cancer Institute, leading the expansion of cancer care services across the system, including spearheading of a comprehensive precision medicine and molecular tumor board program for all cancer types and developing the health system’s new cancer facility, expected to open in 2020.
An internationally recognized brain tumor expert, Dr. Kalkanis currently serves as President of the Congress of Neurological Surgeons, the largest association of its kind. In 2018, he was also named Director of the American Board of Neurological Surgery, the official accrediting and credentialing body for all neurosurgeons practicing in the United States. Actively involved in clinical trials and research, Dr. Kalkanis leads a translational research laboratory investigating the molecular genetic differences between short- and long-term brain tumor survivors with the goal of refining future personalized medicine treatment protocols. He has also served as a visiting professor and guest lecturer for more than 100 national and international audiences and has authored more than 150 peer-reviewed publications.